Michael Bryant's  Instablog

This is some extra info about IntelGenx (IGXT.OB) which I wrote about in my article Rapidly Rising Biotech, Pharmaceutical Companies with Big Potential.

IntelGenx is a drug delivery company focused on the development of oral controlled-release products as well as novel rapidly disintegrating delivery systems. The company uses its unique multiple layer delivery system to provide zero-order release of active drugs in the gastrointestinal tract. IntelGenx has also developed novel delivery technologies for the rapid delivery of pharmaceutically active substances in the oral cavity based on its experience with rapidly disintegrating films.

The company has no-debt, has a cash burn of $2 million per year, and has cash till 2013 without considering upfront payment from upcoming Partnership and without sales from CPI-300, which is expecting approval in December.

As the U.S. navy deploys more ships to the Middle East and North Africa to monitor conflicts in the region, General Dynamics (GD) is set to benefit.  Plus, other divisions could see increased sales.  Further, upgrades and earnings surprise could be in the future.

GD is the largest manufacturer of submarines and destroyers for the U.S. navy.  On March 9^th, the company received a $11.2 million Navy contract for radar and missile defense systems. http://finance.yahoo.com/news/General-Dynamics-gets-112-apf-4138102149.html?x=0&.v=1 This adds to an $11.5 million contract received in September of 2010. 

The company has four main divisions:

Gulfstream manufactures business jets.  The market for business jets seems to be growing with increasing demand from China.  Jet Aviation provides business jet services including maintenance and engineering and controls a fleet of more than 200 aircraft.  Plus, with stricter TSA standards, both units could see an increase in sales.

The Armaments and Technical Products unit manufactures weapon and armament systems, ship missile systems, defensive armor, countermeasures, aircraft gun and ground systems, unmanned aircrafts, and off-road axle and suspension systems.  It is also a leading U.S. producer of biological and chemical detection systems.  The European Land Systems unit manufactures combat vehicles and is a leading producer of armament combat systems and munitions.  The Land Systems unit is a leading provider of combat vehicles including the M1 main battle tank.  The Ordnance and Tactical Systems unit tests and provides munitions and weapons.  This division could be the hardest hit by defense cutbacks.  But unmanned aircrafts are seeing increased demand.

The Advanced Information Systems unit provides intelligence systems to homeland security and defense customers.  The C4 Systems unit provides communication systems mainly to defense and government customers.  The Information Technology provides IT services to defense and homeland security.  The United Kingdom Limited unit contracts armored fighting vehicles (AFV), avionics, tactical systems, chemical and nuclear solutions, and surveillance systems to the British Armed Forces and abroad.  This division may see an increase in spending, especially in homeland security.

Iron Bath Works builds destroyers, while Electronic Boat builds ballistic missile and attack submarines.  NASSCO is the only major ship construction and repair shipyard on the West Coast.   NASSCO is constructing the Navy's Lewis and Clark-class of T-AKE dry cargo-ammunition ships and is working on designing the next generation of Mobile Landing Platform ships. The company also constructs commercial product carriers for domestic cargo transportation.  This division should not see much of any cut in spending.

Below is a breakdown of revenue from each division:

The Information Systems and Technology division provides almost twice as much revenue as the aerospace division.  The only division that seems to be loosing revenue is the Combat Systems.  However, the division experienced a surprise jump in revenue in the 4^th quarter.  The Combat Systems division saw a $405 million decrease in revenue in the 1^st quarter of 2009 to 2010.  Over the same period, the Aerospace division saw a $98 million decrease, the Marine Systems division saw a $30 million decrease, and the Information Systems and Technology division saw a $19 million increase in revenue.  That is a combined $514 million decrease in revenue when comparing the 1^st quarter of 2009 to 2010.

But when comparing 4^th to the following 1^st quarter, the Aerospace division saw an increase of $176 million.  Over the same period, the Combat Systems division saw a $466 million decrease, the Marine Systems division saw a $458 million increase, and the Information Systems and Technology division saw a $284 million increase in revenue.  That is a combined $452 million increase in revenue when comparing the 4^th quarter to the following 1^st quarter.

Taking the comments on division increase or decrease spending in paragraphs 3-6, lets assume that there is exactly no change in increase and decrease of revenues from the 4^th to following 1^st quarter.  That means the Aerospace division makes $1.444 billion, the Combat Systems division makes $2.23 billion, the Marine Systems division makes $1.552 billion, and the Information Systems and Technology division makes $3.148 billion.  Adding that all together is $8.374 billion in revenue.

Comparing it to its top competitors, GD is not cheap.  It has the highest P/S among the group.  On the plus side, it has the 2^nd highest year over year quarterly revenue growth and the lowest percent short.  Notice that the revenue/share is greater than the price for all stocks in the list, meaning all these stocks may be undervalued.  A forward PE of 9.90 is lower than the S&P 500 average PE of 16.40.

One thing that can push GD higher or lower is either upgrades or downgrades.  The company reports 1^st quarter earnings April 27^th before the bell.

Consensus: 

Earnings:  $1.62

Revenue:  $7.94B

The table below shows earnings data.  Earnings per share are non-GAAP.

The graphs above include the earnings estimate which is placed in quarter 13 (the 13^th quarter since the 1^st quarter 2008).  As one can see, both revenue and earnings are expected to fall hard.  In fact, the decline is the steepest in the company’s last 12 quarters.  Will this happen?  Going back to the division data, it probably will not be that big of a cut.

The technicals give mixed signals.  All indicators (MFI, RSI, Stochastic %K and %D, and W%R) are between traditional overbought and oversold signals.  Thus, there is no definite buy or sell signal.  However, when drawing a line, shown in purple, from where the technicals are currently, one can see when prices had the same technical in the past.  The vertical purple lines show every point where the MFI was at the same level.  Three times all four technicals were at the same level at the same time.  Two of these were followed by an increase in price.  They are circled in purple.  The other time was followed by a decrease in price.  They are circled in red.  And one other time, three of the technicals were at the same level at the same time.  It was followed by a decrease in price, and thus is circled in red.  Thus, one can say that the stock has slightly higher odds to move higher.

The price seemed to be moving in a price range upward.  But in the last few weeks, the price has turned flat or even declined, forming a new support and resistance levels.  If the price can break the newly formed 1^st resistance line, it will meet resistance at its old 2^nd resistance line.  Assuming it climbs at about 13 cents a day, it will take 7 days to reach its 1^st resistance line at $77 and, if it breaks it, 100 additional days before it reaches $90.  But any upgrades could increase this time frame.

Source:  Yahoo Finance

Note:  This was the article deleted back in February.  Just posted it for those who want to look at it.  The drug was rejected, as I warned in the article.

Protalix BioTherapeutics (PLX) gets FDA decision tomorrow, Friday February 25^th, on Uplyso, its treatment for Gaucher disease.  “Gaucher disease is a rare genetic disorder in which a person lacks an enzyme called glucocerebrosidase,” causing “harmful substances to build up in the liver, spleen, bones, and bone marrow.” http://www.ncbi.nlm.nih.gov/pubmedhealth/PMH0001590  The drug no doubt works, passing phase 3 trial and getting Special Protocol Assessment from the FDA for the trial design. http://www.fool.com/investing/high-growth/2011/02/23/will-uplyso-get-past-the-fda.aspx However, the FDA did delay approval on the drug the last time it reviewed based on “"validation of the manufacturing process."  The drug is made by plant cells.  Approval will validate their technology, making it the “first FDA approved BLA for recombinant therapeutic proteins using a plant-cell based expression system.” seekingalpha.com/article/252718-ubs-anal... Being the first is always a big jump to undertake.  And noting that the FDA has been safety oriented over the past year, plus the previous delay, makes me think approval may not happen this time either.

A big red flag I see is that “one of the most enthusiastic investors, who pushed Protalix in its first days as a public company - Teva Pharmaceutical Industries Ltd. Chairman Dr. Phillip Frost - sold most of the shares he owned.” seekingalpha.com/article/254351-4-israel...  If he was a big fan, he wouldn’t sell everything before the company’s big moment unless he saw something wrong.  Any insider hints?

Despite my bearish view, approval is a possibility.  Therefore, since I am not 100% certain, it is safest to take a 50-50 strangle.  Assuming it will jump or fall by 40%, I recommend buying both the March 30^th $13 calls and the March 30^th $5 puts.  As long as it goes above $13 or below $5, you will make money.

Special thanks to http://momentumoptionstrading.com/